Rapidly Emerging Antiviral Drug Development Initiative (READDI) United States of America (USA)

Research

Date range: 1 December 2020 - 30 November 2021

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for Rapidly Emerging Antiviral Drug Development Initiative (READDI) published between 1 December 2020 - 30 November 2021 which are tracked by the Nature Index.

Hover over the donut graph to view the Share for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Article Count and Share for Rapidly Emerging Antiviral Drug Development Initiative (READDI)
Count Share
1 0.01

Outputs by subject (Share)

Outputs by subject
Subject Count Share
1 0.01

Share output for the past 5 years

Share per year
2016 2017 2018 2019 2020
0.00 0.00 0.00 0.00 0.07

Compare Rapidly Emerging Antiviral Drug Development Initiative (READDI) with other institutions

Collaboration

Date range: 1 December 2020 - 30 November 2021

International vs. domestic collaboration by Share

  • 96.96% Domestic
  • 3.04% International

Hover over the graph to view the percentage of collaboration.


Top 10 domestic collaborators with Rapidly Emerging Antiviral Drug Development Initiative (READDI) by Share (7 total)

  1. Rapidly Emerging Antiviral Drug Development Initiative (READDI) and The University of North Carolina at Chapel Hill (UNC) (0.79)
    Rapidly Emerging Antiviral Drug Development Initiative (READDI)0.01
    The University of North Carolina at Chapel Hill (UNC)0.78
  2. Rapidly Emerging Antiviral Drug Development Initiative (READDI) and Drug Innovation Ventures at Emory, LLC (DRIVE) (0.10)
    Rapidly Emerging Antiviral Drug Development Initiative (READDI)0.01
    Drug Innovation Ventures at Emory, LLC (DRIVE)0.09
  3. Rapidly Emerging Antiviral Drug Development Initiative (READDI) and UNC Center for AIDS Research (CFAR) (0.10)
    Rapidly Emerging Antiviral Drug Development Initiative (READDI)0.01
    UNC Center for AIDS Research (CFAR)0.09
  4. Rapidly Emerging Antiviral Drug Development Initiative (READDI) and Emory University (0.08)
    Rapidly Emerging Antiviral Drug Development Initiative (READDI)0.01
    Emory University0.06
  5. Rapidly Emerging Antiviral Drug Development Initiative (READDI) and Research Triangle Institute International (RTI International) (0.04)
    Rapidly Emerging Antiviral Drug Development Initiative (READDI)0.01
    Research Triangle Institute International (RTI International)0.03
  6. Rapidly Emerging Antiviral Drug Development Initiative (READDI) and FHI 360 (0.04)
    Rapidly Emerging Antiviral Drug Development Initiative (READDI)0.01
    FHI 3600.03
  7. Rapidly Emerging Antiviral Drug Development Initiative (READDI) and UNC HIV Cure Center (0.02)
    Rapidly Emerging Antiviral Drug Development Initiative (READDI)0.01
    UNC HIV Cure Center0.01

Top 10 international collaborators with Rapidly Emerging Antiviral Drug Development Initiative (READDI) by Share (2 total)

  1. Rapidly Emerging Antiviral Drug Development Initiative (READDI) and Structural Genomics Consortium (SGC) (0.02)
    Rapidly Emerging Antiviral Drug Development Initiative (READDI)0.01
    Structural Genomics Consortium (SGC)0.01
  2. Rapidly Emerging Antiviral Drug Development Initiative (READDI) and GlaxoSmithKline plc. (GSK) (0.02)
    Rapidly Emerging Antiviral Drug Development Initiative (READDI)0.01
    GlaxoSmithKline plc. (GSK)0.00

Relationships

Partner Institutions

Rapidly Emerging Antiviral Drug Development Initiative (READDI) is a research collaboration whose article contributions are accrued to its participating partner institutions below.